Virbac SA (LON:0NM7)

Market Cap	2.16B
Revenue (ttm)	1.14B
Net Income (ttm)	119.71M
Shares Out	n/a
EPS (ttm)	14.25
PE Ratio	18.02
Forward PE	n/a
Dividend	1.11 (0.36%)
Ex-Dividend Date	Jun 25, 2024

Volume	11
Average Volume	536
Open	304.50
Previous Close	304.00
Day's Range	303.00 - 312.00
52-Week Range	253.87 - 330.49
Beta	0.95
RSI	48.68
Earnings Date	Sep 12, 2025

About Virbac

Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1968
• Employees: 5,459
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NM7

Financial Performance

In 2023, Virbac's revenue was 1.25 billion, an increase of 2.53% compared to the previous year's 1.22 billion. Earnings were 121.30 million, a decrease of -0.53%.

Financial numbers in EUR